Does biotech insurance cover patent infringement claims?

Patent infringement is a specific type of intellectual property claim that the standard insurance forms in a biotech program — commercial general liability, products liability, D&O, professional liability — typically exclude. The reason is risk concentration: patent infringement claims in biotech can produce extraordinarily large judgments and the carriers don't want this exposure absorbed into general coverages.

To insure against patent infringement claims, biotechs purchase explicit IP infringement coverage. The market for this coverage has matured substantially; programs are available as sub-limits on professional liability, as part of tech E&O coverage for AI/digital platforms, or as standalone IP infringement defense policies.

Commercial general liability's Coverage B (Personal and Advertising Injury) responds to certain narrow IP claims — typically trademark infringement in advertising and copyright infringement in advertising — but specifically excludes patent infringement.

Professional liability (E&O) for biotech services may respond to claims that the biotech's services or work product infringed third-party rights, depending on the specific policy wording and the nature of the claim. The coverage scope is fact-specific.

D&O may respond to securities claims alleging that the biotech's public statements about IP position were misleading (a securities claim, not a patent infringement claim), but does not respond to the underlying patent infringement claim itself.

Sub-limit on professional liability — typical for biotechs with services components (CRO, consulting), $1M-$3M sub-limit, modest premium.

Part of tech E&O — typical for digital health and AI drug discovery platforms, $2M-$10M, premium varies with the size and complexity of the platform.

Standalone IP infringement defense — typical for late-stage biotech with high-value IP portfolios and active competitive litigation risk. Limits run $5M-$25M; premium is material but can be modest relative to single-claim defense cost.

Patent defense legal expense coverage — a narrower product covering defense costs only (not damages); typically structured as a defense fund with retention thresholds and panel-counsel arrangements.

Operators with substantial IP portfolios facing active competitive landscape — late-stage clinical or commercial biotech in crowded therapeutic areas, medical device operators with patents in active dispute, digital health platforms with algorithmic patent exposure.

Operators contracting with major pharma sponsors where the contract requires IP infringement indemnity from the supplier — the indemnity creates exposure that the supplier needs to insure even if the supplier's standalone risk is modest.

Operators that have received prior cease-and-desist letters or have had IP claims threatened or filed against them.

Willful infringement — most IP coverage excludes claims arising from willful or intentional infringement.

IP that the operator does not own or have licensed rights to — operators cannot insure IP they don't have a legal interest in.

Pre-existing claims known to the operator at policy inception — IP infringement coverage applies prospectively.